Wendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics (NASDAQ:RAPP) Director Wendy B. Young purchased 6,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $61,260. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP opened at $10.51 on Friday. The business’s 50 day simple moving average is $13.54 and its 200-day simple moving average is $18.74. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently modified their holdings of RAPP. Wells Fargo & Company MN lifted its stake in Rapport Therapeutics by 38.9% in the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company’s stock valued at $86,000 after buying an additional 1,352 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the 3rd quarter valued at approximately $34,000. The Manufacturers Life Insurance Company lifted its stake in Rapport Therapeutics by 2.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company’s stock valued at $1,584,000 after buying an additional 1,828 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics in the 4th quarter valued at approximately $34,000. Finally, Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter valued at approximately $41,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.